First AD

Second AD

Overview of FCS

Video content above is prompted by the following:

Please provide an overview of Familial Chylomicronemia Syndrome, or FCS, and Persistent Chylomicronemia. (please note which is genetically confirmed vs clinically diagnosed and; expand on them two

What is the prevalence and disease burden of FCS in the United StatesUS?

What are the signs/symptoms and diagnostic criteria of FCS?

How do you differentiate FCS from other forms of hyperlipidemia?

Treatment of Familial Chylomicronemia Syndrome: A Multidisciplinary Approach

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Familial Chylomicronemia Syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels due to impaired lipoprotein lipase activity. It is genetically confirmed through mutations in genes like LPL, APOC2, APOA5, LMF1, or GPIHBP1. Persistent Chylomicronemia, often clinically diagnosed, results from secondary factors like diabetes or alcohol use. FCS affects approximately 1-2 per million in the US, leading to recurrent pancreatitis and abdominal pain. Differentiation from other hyperlipidemias involves genetic testing and assessing triglyceride response to dietary fat restriction.

Panelists discuss how familial chylomicronemia syndrome (FCS) and persistent chylomicronemia are diagnosed either genetically or clinically, outlining the prevalence and disease burden of FCS in the US, as well as its signs, symptoms, and diagnostic criteria, and how to differentiate FCS from other forms of hyperlipidemia.